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Abstract
Background and Methods—Familial aggregation of lung cancer exists after accounting for
cigarette smoking. However, the extent to which family history affects risk by smoking status,
histology, relative type and ethnicity is not well described. This pooled analysis included 24 case-
control studies in the International Lung Cancer Consortium. Each study collected age of onset/
interview, gender, race/ethnicity, cigarette smoking, histology and first-degree family history of
lung cancer. Data from 24,380 lung cancer cases and 23,305 healthy controls were analyzed.
Unconditional logistic regression models and generalized estimating equations were used to
estimate odds ratios and 95% confidence intervals.
Results—Individuals with a first-degree relative with lung cancer had a 1.51-fold increase in risk
of lung cancer, after adjustment for smoking and other potential confounders(95% CI: 1.39, 1.63).
The association was strongest for those with a family history in a sibling, after adjustment
(OR=1.82, 95% CI: 1.62, 2.05). No modifying effect by histologic type was found. Never smokers
showed a lower association with positive familial history of lung cancer (OR=1.25, 95% CI: 1.03,
1.52), slightly stronger for those with an affected sibling (OR=1.44, 95% CI: 1.07, 1.93), after
adjustment.
Conclusions—The increased risk among never smokers and similar magnitudes of the effect of
family history on lung cancer risk across histological types suggests familial aggregation of lung
cancer is independent of those associated with cigarette smoking. While the role of genetic
variation in the etiology of lung cancer remains to be fully characterized, family history
assessment is immediately available and those with a positive history represent a higher risk
group.
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Introduction
Lung cancer is the leading cause of cancer-related deaths worldwide (1). Current and former
smokers are at greatest risk, but lung cancer does occur among nonsmokers, with varying
rates across countries (2). The association between cigarette smoking and increased risk of
lung cancer is now undisputed. Despite this, less than 20% of smokers develop lung cancer,
suggesting that the effect of tobacco smoke exposure is modified by other variables,
including individual susceptibility (3). The search for a gene or genes associated with
susceptibility is still nascent. Genome wide association studies have independently reported
chromosomal region 15q24-25.1, which contains nicotinic acetylcholine receptor sub-unit
genes, to be associated with increased risk of lung cancer in ever smokers (4-6). These
findings have been replicated among individuals with a family history of lung cancer, and
the relative risk of lung cancer associated with markers in this region are much higher for
familial cases compared to the relative risk observed among sporadic cases (7). Linkage
analysis in families with aggregation of lung cancer also described a region on chromosome
6q23-25 associated with risk of lung cancer (8). The clinical significance of these findings is
still unclear. In the meantime, lung cancer risk models using epidemiologic data have been
developed, and the most parsimonious models for both ever and never smokers include a
family history of cancer variable (9).
Developing risk models for lung cancer are vital, given the report from the National Lung
Screening Trial (NLST), which suggests that low-dose helical computed tomography (CT)
scans may cut deaths from lung cancer by 20% (10). It should be noted these findings were
among individuals 55-74 years of age, with a smoking history of 30+ pack years, and should
not be extended to other populations (11). A crucial component to a successful screening
program is defining a population at high risk. Until screening protocols have been
developed, the main recommendations to reduce risk of lung cancer remain smoking
avoidance, cessation, and limiting exposure to known carcinogens (e.g. radon,
environmental tobacco smoke)(12).
Relatives of individuals with lung cancer may be at higher risk of lung cancer than the
general population. Various smaller studies have provided evidence that familial aggregation
of lung cancer exists after adjusting for the aggregation of cigarette smoking and type of
family relatedness (13, 14). In this study, we performed a pooled analysis of data contributed
to the International Lung Cancer Consortium, in order to describe in greater detail familial
aggregation of lung cancer. Given the large sample size of this analysis, we were able to
perform subgroup analyses examining risk by gender, race/ethnicity, histologic type, age at
diagnosis, and smoking status.
Materials and Methods
Study Population
The International Lung Cancer Consortium (ILCCO) was established in 2004, with the goal
of sharing compatible data from lung cancer epidemiology studies to achieve greater power
than from single studies alone. To date, 57 lung cancer studies are included in ILCCO.
Further details regarding the aims, guidelines and policies of ILCCO are described in Hung
et al.(15).
To be included in the main analysis of familial aggregation of lung cancer, the following
minimum criteria were set. Each study must have collected data regarding the lung cancer
status, age at diagnosis, smoking status of the proband, and vital status (living/deceased) for
the mother, father and siblings of every case and control proband. Additional analyses were
performed in 5 studies that also collected smoking status on each relative in addition to the
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minimum variables. Institutional approval and written informed consent from all subjects
were obtained by the investigator at each study site for each original study and their de-
identified data were submitted to ILCCO for pooling.
Statistical Methods
The individual-level data from each study included the following demographic variables for
the case and control subjects (referred to as probands): gender, ethnicity, age at diagnosis
(cases) or interview (controls), education, smoking status, and pack years smoked, and
histological classification (cases only). Never smokers were individuals who reported
smoking less than 100 cigarettes in their lifetime. Former smokers were individuals who
reported smoking cessation at least 2 years prior to interview. Questions regarding these data
were resolved by the original study investigator.
Relative risks of lung cancer associated with having a first-degree relative with lung cancer
were assessed using unconditional logistic regression models to calculate odds ratios (ORs)
and 95% confidence intervals. Estimates were adjusted for variables that differed
significantly between probands or have been previously shown to be associated with lung
cancer (gender, education, ethnicity, smoking status, pack years) and for study site. Logistic
regression models were created for having any first degree relative with lung cancer, and
then stratified by relative type (father, mother, sibling). To examine interactions between
family history and race, a multiplicative variable of these two factors was added to the
regression model. For all subgroup analyses except for histology, the controls were
restricted to those from the same population (e.g., in the Asian subgroup analysis, only
Asian controls were used). For histology subgroups, all controls (n=23305) were used. For
the sub-set of studies where individual-level information was collected on both affected and
unaffected fathers, mothers, and siblings, in addition to the probands, generalized estimating
equation (GEE) regression models were created to determine whether familial risk of lung
cancer was present after adjustment for risk factors among the relatives of the probands.
These models correct for the correlation between family members (16), and adjusted for
gender and smoking status of each first-degree relative. First, the dataset was restricted to
first-degree relatives, and a variable to indicate whether each individual was related to a case
or control proband was assigned to each subject. GEE models were then constructed for
estimating relative risks in case relatives compared to control relatives, adjusting for
proband age, proband gender, gender of the relative, smoking status of the proband and
smoking status of the relative. SAS (Cary, NC) Version 9.2 was used for all analyses.
Results
Information regarding family history of cancer in first-degree relatives was available for
24,380 cases and 23,399 controls. Of the 57 studies which have contributed data to ILCCO,
24 studies met inclusion criteria for the analysis. Studies from North America accounted for
54% of the datasets analyzed (n=13), 8 were from Europe and 3 were from Asia and
Oceania (Table 1). Population-based controls were ascertained by 11 studies, 8 studies
employed hospital-based controls, and 5 studies utilized both population and hospital-based
control probands (mixed).
Table 2 describes characteristics of case and control probands included in the analysis. Men
accounted for about half of the study population, and the majority of the population was
white (82.3%), followed by Asian (6.8%), and African American (5.4%). Case probands
were significantly more likely to be smokers compared to the control probands (p-
value<0.0001), and among those who reported smoking, cases had a higher number of pack
years compared to controls (p-value<0.0001).
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Risk of lung cancer associated with having a family history of lung cancer in a first-degree
relative (mother, father, sibling) is presented in Table 3. Associations between lung cancer
and family history were found in nearly every stratum after adjusting for proband age,
proband gender, ethnicity, education, smoking status of the proband, pack years, and study
number. Overall, individuals with a first-degree relative with lung cancer had a 1.51-fold
increase in risk of lung cancer compared to individuals without a family history, after
adjustment (95% CI: 1.39-1.63). There is evidence of interaction between smoking status
and family history of lung cancer, with ever smoking individuals with a family history of
lung cancer in a first degree relative having a 3.19-fold increase in risk of lung cancer
compared to never smokers without a first-degree family history of lung cancer after
adjustment (95% CI: 2.03-5.00, data not shown). When stratified by relative type, the
association was greatest for those with a history of lung cancer in a sibling (OR=1.82, 95%
CI: 1.62, 2.05), compared to lung cancer in a father (OR=1.25, 95% CI: 1.13, 1.39) or
mother (OR=1.37 95% CI: 1.17, 1.61). This pattern was similar in male and female
probands. There was a significant interaction between race and family history of lung cancer
(p=0.002, data not shown). The overall association was strongest among Asians (OR=2.38,
95% CI: 1.50, 3.82), then African Americans (OR=1.67, 95% CI: 1.16, 2.40) and whites
(OR=1.46 95% CI: 1.34, 1.58). A family history of lung cancer was associated with lung
cancer in every histological type examined, after adjustment. Among never smoking
individuals, only a history of lung cancer in a sibling was associated with lung cancer
(OR=1.44, 95% CI: 1.07, 1.93). For ever smokers, lung cancer was associated with history
of lung cancer in a father (OR=1.27, 95% CI: 1.13, 1.43), mother (OR=1.40, 95% CI: 1.17,
1.66) and sibling (OR=1.91, 95% CI: 1.68, 2.17), after adjustment. The association was
stronger in cases diagnosed before the age of 50 than in later onset patients (OR=1.83 and
1.45, respectively). Having a history of lung cancer in siblings among probands <50 years
old strengthened the association even further (OR=3.72, 95% CI: 2.00, 6.90), double the
odds ratio for the older cases (OR=1.86, 95% CI: 1.65, 2.09). The number of affected
relatives among cases and controls, by strata, are available in Supplementary Table 1.
The association between lung cancer and family history increased as the number of first-
degree relatives with lung cancer increased. The association between family history and lung
cancer increased from 1.45 (95% CI: 1.34, 1.58) for those individuals who reported one
first-degree relative with lung cancer to 1.97 (95% CI: 1.59, 2.45) for those individuals with
2 or more first-degree affected relatives (data not shown).
Tables 4 and 5 include studies where individual-level information was collected on both
affected and unaffected fathers, mothers, and siblings, in addition to the probands. As seen
in Table 4, data were available for mothers of 6297 cases and 5907 controls, with 240 case
mothers having lung cancer (3.8%) and 171 control mothers having lung cancer (2.9%).
Data were also available for 6,263 fathers of cases and 5,886 fathers of controls, with 453
case fathers having lung cancer (7.2%) and 363 control fathers having lung cancer (6.2%).
Data were available for 18,948 siblings of cases and 16,625 siblings of controls, with 724
case siblings reported to have lung cancer (3.8%) and 282 control siblings reported to have
lung cancer (1.7%). Similar mean ages at diagnosis were reported for case and control
fathers (p-value=0.16), mothers (p-value=0.08) and siblings (p-value=0.72).
Table 5 presents the strength of familial aggregation of lung cancer after adjusting for
proband age, proband gender, proband smoking status, relative’s gender, and relative’s
smoking status. The association with family history was 1.55-fold greater in first-degree
relatives of cases compared to relatives of controls (95% CI: 1.39, 1.73), after adjustment.
The association between lung cancer and family history was elevated for case relatives in all
subgroups compared to control relatives. Family history was a stronger risk factor for
relatives of early-onset (<50 years of age) cases (OR=1.97, 95% CI: 1.51, 2.58) than for
Coté et al. Page 5
Eur J Cancer. Author manuscript; available in PMC 2013 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
those related to someone with later onset disease (OR=1.53, 95% CI: 1.36, 1.72). The
association was greater for those who had a sibling with lung cancer (OR=1.96, 95% CI:
1.65, 2.34) compared to a father (OR=1.33, 95% CI: 1.13, 1.57) or mother (OR=1.39, 95%
CI: 1.12, 1.75) with the disease. In a sub-analysis of siblings with never smoking parents,
the association between having a first-degree relative with lung cancer and lung cancer risk
remained (OR=2.18, 95% CI: 1.52-3.11) after adjustment (data not shown). Never smoking
relatives of cases were somewhat more likely to have lung cancer compared to never
smoking relatives of controls (OR=1.31, 95% CI: 0.96, 1.78), but this association was not
statistically significant. Individuals who were ever smokers and related to a case were 1.57-
fold more likely to have lung cancer than smokers who were related to a control (95% CI:
1.41, 1.76).
Discussion
The results presented here represent the most comprehensive analysis of the association
between family history of lung cancer and lung cancer since the first strong evidence of
familial aggregation was reported nearly 50 years ago (17). To date, this is the largest pooled
analysis which incorporated a traditional case-control analysis and also used data from
individual family members to examine risk adjusted for gender and smoking status of each
relative. Individuals with family history in a first-degree relative are at an approximate 50%
increased risk of lung cancer compared to those without a family history, and this
association remains regardless of gender, race/ethnicity, histological type and after adjusting
for other known lung cancer risk factors.
The majority of lung cancers are diagnosed in current or former smokers, and environmental
tobacco smoke also increases risk (18, 19). Given the strong evidence linking lung cancer
etiology to well-identified occupational or environmental sources, less research has focused
on other causes of this disease, including the influence of family history. Twin studies,
especially those that can compare concordance between monozygotic and dizygotic twins,
can provide information on whether familial aggregation is due to inherited or
environmental factors. Evidence of limited heritability of lung cancers has been reported
from population-based registry data in Utah, Sweden, Denmark and Finland (20-22). Even
in these large, population-based studies, power is limited for most cancers, including lung.
The magnitude of risk associated with having a family history of lung cancer are similar to
those associated with familial aggregation of colon cancer (23), prostate cancer (24), and
breast cancer in non-BRCA families (25). Stronger associations have been reported when
the relative had early-onset disease for these cancers (23, 26, 27), as well as for lung cancer
(28-30). In this pooled analysis, the association was stronger for individuals who were
diagnosed with lung cancer prior to age 50, or who had a family history of lung cancer in a
relative under the age 50. The difference was most pronounced among siblings, with the
odds in early-onset lung cancer nearly double the odds in later onset probands.
Overall, having a sibling with lung cancer conferred the strongest association, and siblings
of cases were at increased risk compared to siblings of controls. Aggregation studies of other
cancer types such as prostate (31, 32) and breast (25) also report evidence of a stronger
association with affected siblings compared to parents, yet this is less established for colon
cancer (33). The association between family history and lung cancer remained for siblings
even after adjustment for cigarette smoking in the relative. Similarly, among never smoking
probands, the association was greater for those who report lung cancer in a sibling, rather
than a parent. The association also remained in siblings from non-smoking households (i.e.
both parents were never smokers). Finally, after adjustment for smoking in both the proband
and the sibling, there remained strong evidence of an association between family history and
lung cancer in the siblings of cases compared to the siblings of controls. Relative type
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should be considered when assessing risk associated with family history of lung cancer. In
general, an elevated risk of disease in siblings signals a recessive effect (34). The elevated
risk from affected siblings might be a result from shared environment exposures childhood,
or indicate there are recessive genes involved. In the five studies that provided information
on all siblings, cases were not more likely to have a sibling compared to controls (82.4% and
83.8%, respectively), and sibships were similar in size, with an average of three siblings for
both cases and controls. Adjusting for number of siblings did not change our results.
Nevertheless, another factor that needs to be considered when interpreting the strong sibling
risk is the age distribution, as affected siblings often have younger ages of onset compared
to the affected parents of the case probands. In our study, the mean age of diagnosis for
affected siblings and affected parents of the index cases was 60.2 and 66.2, respectively.
Therefore, the stronger familial relative risks observed in siblings might be partially
associated with an earlier age of onset. These findings may also be the result of the proband
having greater recall of the cancer status of their generation (versus their parent’s
generation) and better diagnostic techniques in later years, but could also represent evidence
of the genetic contribution to lung cancer etiology.
Most studies of lung cancer and familial aggregation included mainly non-small cell lung
cancers. While it is difficult to ascertain the histology of lung cancer in the relatives, we
were able to ascertain the histological type of lung cancer for the probands and to stratify
results according to type. Despite the different etiologies and outcomes associated with
various histological types, the odds ratios fell in a fairly narrow range (ORrange 1.28-1.81).
For example, the rare (~1%) carcinoid tumors of the lung, which are not considered to be
smoking-associated and are characterized by an excellent overall survival (35), showed an
association with a positive family history of lung cancer (OR=1.28, 95% CI: 1.13-1.45),
confirming in a large dataset early reports from Hassan et al. (2008)(36). The association
with more common (15%) and lethal small cell carcinomas (37, 38) is slightly higher
(OR=1.51, 95% CI: 1.33, 1.70), as anticipated by a recent meta-analysis (39). Overall, the
similar magnitudes of the effect of family history on lung cancer across various histological
types suggest that familial aggregation may be independent of the association with cigarette
smoking. The hypothesis that familial aggregation of lung cancer may be associated with
traits which act independently of cigarette smoking has received support from the results of
a follow up study of the chromosome 6q region which reports a lung cancer risk-associated
haplotype irrespective of degree of smoking yielded similar risk in carriers (40). The search
for other risk factors unrelated to smoking remains crucial, given the number of lung cancer
seen among never smokers.
Global estimates suggest that approximately 25% of lung cancer cases world-wide occur
among never smoking individuals (41, 42). In this analysis, approximately 14% of all lung
cancers were diagnosed in never smokers, and family history of lung cancer was associated
with having lung cancer. Various other exposures that were unmeasured in these populations
may account for some of this risk, although studies among never smokers with lung cancer,
even after adjusting for other known carcinogenic exposures, support family history as an
important risk factor (43-45).
The association between having a family history of lung cancer in a first-degree relative and
lung cancer varies by ethnicity. The associations were highest among Asians and lowest
among whites, with estimates for African Americans falling in between. While some studies
have reported differences in risk of lung cancer associated with cigarette smoking by race/
ethnicity, (46-48) few report estimates for family history by race/ethnicity, as study
populations of individual studies are relatively homogenous. In the current pooled analysis,
odds ratios were higher for African Americans, but not statistically different from results in
the white populations. Studies investigating Asian populations reported risk estimates for
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familial aggregation of lung cancer similar to the 2-fold increases found in the present
pooled analysis (49, 50). Lower background rates of disease may account for these
apparently stronger associations in the Asian population. As smoking patterns,
environmental and occupational exposures, diet, and genetics differ by race/ethnicity, it is
not unexpected that the strength of the association between family history and lung cancer
risk would also vary.
The findings presented are not without limitations. First, all studies relied on self-report of
family history and thus may be prone to recall bias. Confirming each lung cancer among
relatives would be ideal but time and cost-prohibitive. Studies that have validated the
reported family history through another source consistently report high accuracy (sensitivity
>0.80) for lung cancers (51-53). Similarly, we were unable to perform a standardized
pathologic review to confirm histological type, in the probands or the affected relatives.
Next, the methodologies used to ascertain controls differed among the studies. When we
limited our analyses to studies using the same control source, findings were essentially the
same. Only parents and siblings are included in our analysis, as six studies did not collect
information on offspring, and another two studies were focused on early-onset disease,
where the majority of the offspring were under 21 years of age. Lastly, pooled analyses are
limited by the number of common variables collected by each study. Age, gender, ethnicity,
education and smoking history were collected for all study subjects, which are the major
known risk factors for lung cancer. It is possible that there remains residual confounding by
smoking, as smoking status does not fully assess tobacco smoke exposure. Information on
environmental tobacco smoke exposure (in childhood or as an adult) was not collected in a
uniform manner, therefore we were not able to adjust for it in a standardize manner, hence
our findings may be confounded by this omission. Relative information was more likely to
be missing certain variables compared to proband data, and we did not adjust models for
family size, as this was not available for the majority of the studies. When we restricted our
analyses to those studies with a family size variable, the results were not significantly
different.
In summary, family history is a simple proxy for genetic risk, and is influenced by both
shared and individual environmental exposures. The association between lung cancer and
family history of lung cancer remains even after adjustment for smoking. Unlike germline
mutation testing, family history assessment is fairly straightforward and inexpensive to
obtain while taking a patient’s history. While the role of genetic variation in the etiology of
lung cancer is not yet defined, family history assessment is immediately available and those
with a positive history represent a higher risk group. A positive family history of lung cancer
should possibly be one of the variables considered in the selection of a population eligible
for lung cancer screening.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 2
Characteristics of probands included in the familial aggregation analysis
Cases (n=24380) Controls (n=23305) p-value
Gender
Men 13833 (56.7%) 12529 (53.8%) <0.0001
Women 10547 (43.3%) 10776 (46.2%)
Age
<30 73 (0.3%) 476 (2.0%) <0.0001
30≤age<40 551 (2.3%) 1388 (6.0%)
40≤age<50 2551 (10.5%) 3236 (13.9%)
50≤age<60 5458 (22.4%) 5764 (24.7%)
60≤age<70 7813 (32.3%) 7012 (30.1%)
70≤age<80 6480 (26.6%) 4689 (20.1%)
80+ 1454 (5.9%) 740 (3.2%)
Race/Ethnicity
White/Caucasian 20069 (82.3%) 19303 (82.8%) <0.0001
Hispanic/Latino 440 (1.8%) 670 (2.9%)
African American 1304 (5.4%) 1691 (7.3%)
Asian 1656 (6.8%) 1282 (5.5%)
American Indian and Alaskan
Native
185 (0.8%) 33 (0.1%)
Hawaiian/Pacific Islander 398 (1.6%) 150 (0.6%)
Other 169 (0.7%) 152 (0.7%)
Missing/Unknown 159 (0.7%) 24 (0.1%)
Education *
Low 6332 (26.0%) 4550 (19.5%) <0.0001
Medium 9023 (37.0%) 7800 (33.5%)
High 6459 (26.5%) 8513 (36.5%)
Missing 2566 (10.5%) 2442 (10.5%)
Type of Smoker
Never 3301 (13.5%) 8497 (36.5%) <0.0001
Ever** 20961 (86.0%) 14160 (60.8%)
 Former 7940 (32.6%) 7836 (33.6%)
 Current 9877 (40.5%) 5287 (22.7%)
Missing 118 (0.5%) 648 (2.8%)
Mean Pack Years† (SD) 44.3 (33.3) 20.4 (25.8) <0.0001
Histology
Small cell carcinoma 2358 (9.7%)
Non-small cell carcinomas‡ 18616 (76.4%)
 Squamous cell carcinomas 5781 (23.7%)
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Cases (n=24380) Controls (n=23305) p-value
 Large cell carcinomas 1099 (4.5%)
 Adenocarcinoma 9285 (38.1%)
 Bronchioloalveolar carcinoma
  (BAC)
896 (3.7%)
 Non small cell carcinoma, not
 otherwise specified
1555 (6.4%)
Carcinoma§ 1797 (7.4%)
Carcinoid 347 (1.4%)
Others/missing 1262 (5.2%)
*
Low=less than high school, medium=high school diploma or equivalent or some college, high=college degree
**
Includes former smokers, current smokers, and subjects who were either former or current smokers
†
Pack years of smoking was missing for 9.61% of cases and 14.56% for controls
‡Non-small cell includes squamous cell, large cell, adenocarcinomas, bronchioloalveolar carcinoma , and non-small cell carcinoma, not otherwise
specified
§No further detail available
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Table 3
The association between family history of lung cancer and lung cancer, by relative type
Family History of
Lung Cancer in
1st Degree
Relative
Family History of
Lung Cancer in
Father
Family History of
Lung Cancer in
Mother
Family History of
Lung Cancer in
Sibling
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Overall 1.51 (1.39,1.63) 1.25 (1.13,1.39) 1.37 (1.17,1.61) 1.82 (1.62,2.05)
Proband Gender
Male 1.53 (1.37,1.70) 1.23 (1.06,1.43) 1.32 (1.05,1.66) 2.07 (1.76,2.45)
Female 1.48 (1.33,1.65) 1.27 (1.09,1.48) 1.43 (1.15,1.77) 1.59 ( 1.35,1.87)
Proband Ethnicity
White 1.46 (1.34,1.58) 1.19 (1.07,1.34) 1.37 (1.16,1.62) 1.77 (1.56,2.00)
Black/African American 1.67 (1.16,2.40) 1.48 (0.87,2.54) 1.13 (0.55,2.30) 2.07 (1.19, 3.60)
Asian 2.38(1.50, 3.82) 2.82(1.54, 5.70) 0.97(0.39,2.38) 4.35(1.83,10.34)
Proband Histology
Small cell carcinoma 1.51 (1.33,1.70) 1.33 (1.13,1.57) 1.31 (1.00,1.73) 1.63 (1.36,1.95)
Non-small cell carcinoma 1.58 (1.44, 1.73) 1.40 (1.23,1.59) 1.28 (1.07,1.54) 1.77 (1.55,2.02)
 Squamous cell
 carcinoma
1.54 (1.39,1.72) 1.32 (1.14,1.53) 1.16 (0.91,1.49) 1.85 (1.59,2.16)
 Large cell carcinoma 1.81(1.60,2.06) 1.55(1.30,1.92) 1.58(1.25,2.10) 1.23(1.78,2.56)
 Adenocarcinoma 1.59 (1.45,1.74) 1.25 (1.10,1.43) 1.61 (1.34,1.93) 1.85 (1.61,2.12)
 BAC 1.56(1.45, 1.69) 1.09(0.90, 1.35) 1.68(1.24,2.12) 1.93(1.64,2.70)
 Non-small cell
 carcinoma, nos Carcinoma
1.78 (1.58,2.01) 1.48 (1.24,1.75) 2.24 (1.78,2.83) 1.73 (1.44,2.08)
Carcinoid 1.28(1.13, 1.45) 0.92(0.69, 1.10) 1.48(1.16, 1.92) 1.78(1.48, 2.42)
Others/missing 1.30(1.17, 1.48) 1.10(0.96, 1.35) 1.20(0.95, 1.62) 1.85(1.55, 2.30)
Proband Smoking Status
Never Smokers 1.25 (1.03,1.52) 1.09 (0.82,1.45) 1.10 (0.74,1.66) 1.44 (1.07,1.93)
Ever Smokers 1.55 (1.42,1.68) 1.27 (1.13,1.43) 1.40 (1.17,1.66) 1.91 (1.68,2.17)
 Former Smokers 1.46 (1.29,1.65) 1.23 (1.03,1.47) 1.26 (0.97,1.62) 1.83 (1.53,2.18)
 Current Smokers 1.57 (1.37,1.79) 1.33 (1.11,1.59) 1.51 (1.15,1.99) 1.85 (1.48,2.32)
Proband Age at Onset
<50 1.83 (1.47,2.28) 1.68 (1.28,2.20) 1.51 (1.04,2.20) 3.72 (2.00,6.90)
50+ 1.45 (1.33,1.57) 1.10 (0.97,1.24) 1.27 (1.06,1.52) 1.86 (1.65,2.09)
All ORs are adjusted for age, gender, ethnicity, education, smoker type, pack years and study site, where appropriate.
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Table 4
Characteristics of relatives included in the familial aggregation analysis using generalized estimating
equations
Case Relatives Control Relatives P-value
Mothers (n= 12204) n=6297 n=5907
 Ever Smoker 2123 (38.0%) 2270 (40.4%) 0.009
 Never Smoker 3465 (62.0%) 3349 (59.6%)
Number (%) affected w/Lung cancer: 240 (3.8%) 171 (2.9%)
 Median age at diagnosis 68 70
 Mean age at diagnosis (±SD) 66.8±13.0 69.0±10.4 0.08
 Missing age at diagnosis 6 (2.5%) 4 (2.3%) 0.92
Fathers (n= 12149) 6263 5886
 Ever Smoker 3945 (72.7%) 3939 (72.2%) 0.57
 Never Smoker 1483 (27.3%) 1517 (27.8%)
Number (%) affected w/Lung cancer: 453 (7.2%) 363 (6.2%)
 Median age at diagnosis 65 67
 Mean age at diagnosis (±SD) 64.8±10.4 65.9±10.8 0.16
 Missing age at diagnosis 27 (6.0%) 12 (3.3%) 0.08
Siblings (n= 35573) 18948 16625
 Ever Smoker 9869 (59.1%) 8107 (51.5%) <0.0001
 Never Smoker 6819 (40.9%) 7635 (48.5%)
Number (%) affected w/Lung cancer: 724 (3.8%) 282 (1.7%)
 Median age at diagnosis 60 61
 Mean age at diagnosis (±SD) 60.2±11.3 60.0±11.3 0.72
 Missing age at diagnosis 27 (3.7%) 11 (3.9%) 0.90
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Table 5
Odds ratios (95% confidence interval) of risk of lung cancer among first-degree relatives of cases compared to
first-degree relatives of controls among subjects included in the generalized estimating equations analysis
# affected
relatives with
lung cancer
# unaffected
relatives
Lung Cancer Risk among First-
Degree Relatives
Adjusted OR (95%CI)
Overall 2233 57693 1.55 (1.39, 1.73)
Proband Gender
 Male 969 26230 1.34 (1.14, 1.58)
 Female 1264 31463 1.74 (1.50, 2.00)
Proband Ethnicity
 White 2093 51842 1.53 (1.37, 1.71)
 Black/African American 122 5306 2.09 (1.28, 3.42)
Proband Histology
 Small cell carcinoma 88 1973 2.45 (1.72, 3.48)
 Non-small cell carcinoma 1167 24738 2.46 (2.02, 2.98)
Proband Smoking Status
 Never Smokers 393 14972 1.38 (1.08, 1.75)
 Ever Smokers 1833 42634 1.57 (1.42, 1.74)
  Ex-Smokers 989 20837 1.62 (1.38, 1.91)
  Current Smokers 841 21670 1.61 (1.34, 1.93)
Proband Age of Onset
  <50 298 15184 1.97 (1.51, 2.58)
  50+ 1935 42509 1.53 (1.36, 1.72)
Relationship to Proband
  Father 816 11333 1.33 (1.13, 1.57)
  Mother 411 11793 1.39 (1.12, 1.75)
  Siblings 1006 34567 1.96 (1.65, 2.34)
Relative Smoking Status
  Never Smoker 177 24091 1.31 (0.96, 1.78)
  Ever Smoker 1750 28503 1.57 (1.41, 1.76)
ORs adjusted for: gender of proband, proband ethnicity, proband histology, proband smoking status, proband age of onset, relationship to proband,
gender of relative, smoking status of relative (where appropriate).
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